Drug Search Results
More Filters [+]

Empagliflozin

Alternative Names: empagliflozin, jardiance, bi 10773, bi10773, bi-10773, synjardy xr, trijardy xr, glyxambi, synjardy, VORETA
Latest Update: 2024-07-11
Latest Update Note: Clinical Trial Update

Product Description

Empagliflozin is an orally available competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity. Upon oral administration, empagliflozin selectively and potently inhibits SGLT2 in the kidneys, thereby suppressing the reabsorption of glucose in the proximal tubule.

Mechanisms of Action: SGLT2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Heart Failure | Acidosis | Diabetic Ketoacidosis | General Diabetes | Type 2 Diabetes | Type 1 Diabetes | Acidosis | Diabetic Ketoacidosis | General Diabetes | Type 2 Diabetes | Pancreatitis | Type 1 Diabetes | Acidosis | Diabetic Ketoacidosis | General Diabetes | Type 2 Diabetes | Pancreatitis | Type 1 Diabetes | Acidosis | Diabetic Ketoacidosis | General Diabetes | Type 2 Diabetes

Known Adverse Events: Urinary Tract Infections | Headache | Asthenia | Diarrhea | Flatulence | Nasopharyngitis | Pharyngitis | Enteritis | Gastroenteritis | Respiratory Tract Infections | Constipation

Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Empagliflozin

Countries in Clinic: Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Ghana, Greece, Hungary, India, Indonesia, Israel, Italy, Japan, Jordan, Korea, Malaysia, Mexico, Nepal, Netherlands, Norway, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Ukraine, United Kingdom, United States, Unknown Location, Vietnam

Active Clinical Trial Count:

Highest Development Phases

Phase 3: COVID-19|Congenital Heart Defects|Diabetes, Gestational|Heart Failure|Heart Failure, Acute|Heart Failure, Chronic|Heart Failure, Diastolic|Heart Failure, Systolic|Hypoglycemia|Kidney Diseases|Kidney Failure, Chronic|Myocardial Infarction|Severe Acute Respiratory Syndrome|Shock, Cardiogenic|Tricuspid Valve Insufficiency|Type 2 Diabetes

Phase 2: Kidney Calculi|Liver Cirrhosis|Liver Failure|Nephrolithiasis

Phase 1: General Diabetes|Healthy Volunteers|Type 1 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

U1111-1302-4422

P3

Not yet recruiting

Heart Failure

2027-11-15

54%

U1111-1302-4422

P3

Not yet recruiting

Heart Failure

2027-11-15

54%

2021PI218

P3

Not yet recruiting

Shock, Cardiogenic

2026-08-01

RECOVERY

P3

Recruiting

Severe Acute Respiratory Syndrome|COVID-19

2026-06-30

CT-L03-301

P3

Not yet recruiting

Type 2 Diabetes

2026-05-31

Recent News Events